|
Age at diagnosis (years old)
|
56 (18–75)
|
|
No. of patients by gender
| |
|
Male
|
396 (66.1%)
|
|
Female
|
203 (33.9%)
|
|
No. of patients by tumor differentiation
| |
|
Low
|
63 (10.5%)
|
|
Moderate
|
458 (76.5%)
|
|
High
|
78 (13.0%)
|
|
Distance to anal verge (cm)
|
5.0 (1.0–15.0)
|
|
No. of patients by clinical T stage
| |
|
cT4b
|
26 (4.3%)
|
|
cT4a
|
249 (41.6%)
|
|
cT3
|
314 (52.4%)
|
|
cT2
|
10 (1.7%)
|
|
cT1
|
0 (0.0%)
|
|
No. of patients by clinical N stage
| |
|
cN2
|
213 (35.6%)
|
|
cN1
|
280 (46.7%)
|
|
cN0
|
106 (17.7%)
|
|
CEA (ng/ml)
|
4.2 (0.0-392.0)
|
|
CA19-9 (U/ml)
|
13.8 (0.0-985.6)
|
|
ApoAI (g/L)
|
1.19 (0.51–2.05)
|
|
ApoB (g/L)
|
0.90 (0.39–1.78)
|
|
ApoB-to-apoAI ratio
|
0.75 (0.23–1.92)
|
|
No. of patients by radiotherapy technique
| |
|
3DCRT
|
163 (27.2%)
|
|
IMRT
|
436 (72.8%)
|
|
No. of patients by TRG
| |
|
5
|
16 (2.7%)
|
|
4
|
107 (17.8%)
|
|
3
|
202 (33.7%)
|
|
2
|
137 (22.9%)
|
|
1
|
137 (22.9%)
|
|
No. of patients by pathological T stage
| |
|
pT4b
|
13 (2.2%)
|
|
pT4a
|
36 (6.0%)
|
|
pT3
|
240 (40.1%)
|
|
pT2
|
135 (22.5%)
|
|
pT1
|
24 (4.0%)
|
|
pT0
|
151 (25.2%)
|
|
No. of patients by pathologic N stage
| |
|
pN2
|
26 (4.3%)
|
|
pN1
|
103 (17.2%)
|
|
pN0
|
470 (78.5%)
|
|
Chemotherapy cycle
|
7 (4–10)
|
|
No. of patients by active viral hepatitis
| |
|
Yes
|
82 (13.7%)
|
|
No
|
517 (86.3%)
|
